top of page
Partners meeting at CIPHE facilities

Partnerships

CIPHE accelerates biomedical innovation through strategic partnerships and plays a key role in major academic and industrial research networks across immunology, oncology, and infectious diseases.

Key Illustrations of CIPHE’s engagement with Scientific and Academic Partnerships

CIPHE actively cultivates broad scientific partnerships and consortium-based collaborations that connect academic research with translational applications.
Through these multi-institutional consortia, the institute engages with leading research groups and academic partners to drive innovation.

>

CIPHE participated in major collaborative research projects such as the Labex DCBIOL (2011–2022) with Institut Curie and CIML on immune and inflammatory mechanisms, and the RHU Pioneer Project (2017–2024) involving multiple leading academic and industrial partners.
Large Collaborative Projects

>

In 2019, CIPHE partnered with The Jackson Laboratory (JAX) to develop humanized mouse models for cancer and infectious disease research, combining JAX’s genetic expertise with CIPHE’s immunophenotyping capabilities through its A3L3 module.
CIPHE–JAX Humanized Mice

>

During the COVID-19 pandemic, CIPHE launched a SARS-CoV-2 Task Force and became the first European platform to offer A3L3 mouse models for SARS-CoV-2 therapeutic evaluation, joining INFRAFRONTIER’s pipeline and European consortia like ISIDORe.
COVID-19 Research Leadership

>

CIPHE developed 15 genetically modified mouse lines targeting the TCR signaling pathway, providing insights into systemic TCR signal propagation and redundancy, and supporting advances in precision immunotherapy through high-impact publications.
TCR Mouse Models & Publications

>

CIPHE actively participates in national and international academic networks, funding programs, and scientific symposia, contributing to infrastructures like PHENOMIN, INFRAFRONTIER, and Marseille Immunopôle, enhancing its scientific credibility and visibility.
Academic Networks Integration

Selected scientific partnerships examples

Selected large-scale national and European projects and funding schemes.

Key Illustrations of CIPHE’s engagement with its socio-economic and cultural environment.

During the current mandate, CIPHE has significantly strengthened its cooperation with various industrial partners. This has led to its involvement in several multi-year projects and funding programs with leading companies in the fields of immuno-oncology, inflammation, and infectious diseases, including Merck, SANOFI, Galderma, Janvier Labs, and Onco-Design.

Strategic Partnership with Merck (via PHENOMIN)

This collaboration enabled the characterization of over 30 mouse models and the execution of dozens of immuno-oncology studies. Its quality has been recognized several times, with Hervé Luche receiving Merck’s 2018 prize for 'Best External Collaborator of the Year,' and the CIPHE team being awarded a collective prize in 2023 to celebrate 10 years of collaboration.

R&D Collaboration with SANOFI

CIPHE developed and characterized several genetically engineered mouse models expressing humanized molecules involved in modulating lymphocyte activation during anti-tumor immune responses, directly supporting SANOFI’s immuno-oncology pipeline.

Contracts with Galderma

Through collaborative research contracts, CIPHE enhanced its expertise in cutaneous inflammatory models, contributing to Galderma's development of new dermatological therapeutics.

Joint Innovation with Janvier Labs

Initiated in 2019 by Frédéric Fiore, the partnership between CIPHE and Janvier Labs brought together their complementary expertise to develop differentiated preclinical products that neither entity could have created independently. These include mouse/rat models tailored for high-content immunophenotyping, particularly relevant for advancing research in cancer immunotherapy, inflammation, and autoimmune diseases. Notably, CIPHE has characterized about twenty immunodeficient mouse models developed by Janvier Labs for oncology research.

Rapid COVID-19 Response with Onco-Design

In response to the pandemic, CIPHE demonstrated both agility and scientific rigor by establishing a complete COVID-19 research offering within just six months. This enabled the secure execution of in vitro and in vivo pharmacology studies, supporting the evaluation of new preventive, therapeutic, and vaccine strategies against COVID-19.

bottom of page